Research programme: interleukin-4 therapeutics - Medicenna Therapeutics

Drug Profile

Research programme: interleukin-4 therapeutics - Medicenna Therapeutics

Alternative Names: IL4-ECs; IL4-Empowered Cytokines; Interleukin-4 Empowered Cytokines™; MDNA 56; MDNA-57

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medicenna Therapeutics
  • Class Antineoplastics; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 24 Oct 2017 Medicenna Therapeutics in-licenses patent for Interleukin-4 Superkines from Stanford University
  • 24 Oct 2017 Stanford University has patent protection for Interleukin-4 Superkines
  • 16 Mar 2017 Medicenna Therapeutics enter into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to develop fusion protein therapeutics targeting the IL 4 receptor and to advance preclinical development of Empowered Cytokines™ based on IL 4 and IL 13 Superkine™ platform
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top